BEIJING, May 22 (Xinhua) -- Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) announced Monday that it had inked deal with Takeda Pharma AG to buy 100 percent stake of latter’s wholly owned subsidiary Takeda Chromo Beteiligungs AG through its investment subsidiary in Hong Kong with 144 million U.S. dollars (915 million yuan).
This means an indirect purchase of 26.34 percent stake of Guangdong Techpool Bio-pharma Co., Ltd in which SPH's stake would rise to 67.14 percent from previous 40.8 percent.
Through the purchase, SPH would fill up its product blank in natural urine protein drugs and subdivision treatment of critical illness to further enrich its product line and improve competitiveness. (Edited by Niu Huizhe, niuhuizhe@xinhua.org)
A single purchase
